Lasofoxifene (tartrate)

Lasofoxifene (CP-336156) tartrate is an orally active and selective estrogen receptor modulator (SERM) [1]. Lasofoxifene tartrate exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene tartrate can be used for the research of breast cancer and postmenopausal osteoporosis[1][2].

Product Specifications

CAS Number

[190791-29-8]

Product Name Alternative

CP-336156 (tartrate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Estrogen Receptor/ERR

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Field of Research

Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/Lasofoxifene-Tartrate.html

Purity

99.93

Solubility

DMSO : 83.33 mg/mL (ultrasonic)

Smiles

OC1=CC=C2[C@@H](C3=CC=C(OCCN4CCCC4)C=C3)[C@@H](C5=CC=CC=C5)CCC2=C1.O=C(O)[C@@H](O)[C@H](O)C(O)=O

Molecular Formula

C32H37NO8

Molecular Weight

563.64

Precautions

H302, H315, H319, H335

References & Citations

[1]Andersson A, et al. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford) . 2016 Mar;55 (3) :553-63.|[2]Lainé M, et al. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 May 12. 23 (1) :54. |[3]Andreano KJ, et al. The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. Mol Cancer Ther. 2020 Jul. 19 (7) :1395-1405.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

BioRxiv. 2024 Jun 2:2024.05.28.596307.|Gynecol Oncol. 2019 Jul;154 (1) :199-206.|Mol Cancer Ther. 2020 Jul;19 (7) :1395-1405.|NPJ Breast Cancer. 2022 Dec 14;8 (1) :130.|NPJ Breast Cancer. 2025 Nov 12;11 (1) :125.